medigraphic.com
ISSN 0016-3813 (Impreso)

2003, Número 2

<< Anterior Siguiente >>

Gac Med Mex 2003; 139 (2)


Receptores y funciones del TGF-beta, una citocina crucial en la cicatrización.

García-Sainz JA, Vilchis-Landeros MM, Juárez P, López-Casillas F, Hernández-Pando R, López-Casillas F, Massagué J

Idioma: Español
Referencias bibliográficas: 134
Paginas: 126-143
Archivo PDF: 176.31 Kb.


FRAGMENTO

Introducción Una de las complicaciones más frecuentes y generalmente fatal de la diabetes mellitus es la insuficiencia renal. Éste es un grave problema de salud en México, pues no sólo su incidencia va en aumento, sino que la población mexicana parece ser particularmente susceptible a ella. Garza y colaboradores han encontrado que en los pacientes diabéticos tipo II (no dependientes de insulina) de origen mexicano, el deterioro de la función renal es más acelerado que en grupos de diferente origen étnico. En la década pasada el entendimiento de la fisiopatología de la nefropatía, de etiología diabética en particular y de otras etiologías en general, ha revelado que uno de los principales mediadores del daño renal es una poderosa citocina llamada Transforming Growth Factor tipo beta (TGF-β).3,4 De ahí que, en principio, un tratamiento racional de las nefropatías debería basarse en inhibidores del TGF-β, los cuales, necesariamente, resultarán del conocimiento derivado de los mecanismos de señalamiento del TGF-β. Este campo de estudio ha tenido un desarrollo espectacular en los últimos años con el consecuente desarrollo de nuevos conceptos y la identificación de moléculas transductoras de sus señales, las cuales podrían ser blancos para una intervención terapéutica anti-TGF-β. En esta parte del simposio discutiremos conceptos básicos de la biología del TGF-β, sus mecanismos fisiopatológicos, y los agentes neutralizadores del TGF-β más promisorios para una eventual terapia en humanos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. I. El papel fisiopatológico del TGF-β en las nefropatías de diversas etiologías: los inhibidores del TGF-β como agentes terapéuticos potenciales


  3. Escobedo-De la Peña J, Rico-Verdín B. Incidencia y letalidad de las complicaciones agudas y crónicas de la diabetes mellitus en México. Salud Pública de Méx 1996;38:236-242.

  4. Garza R, Medina R, Basu S, Pugh JA. Predictors of the rate of renal function decline in non-insulin-dependent diabetes mellitus. Am J Nephrol 1997;17:59-67.

  5. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-b in kidney diseases. Am J Physiol 1994;266: F829-F842.

  6. Reeves WB, Andreoli TE. Transforming growth factor b contributes to progressive diabetic nephropathy. Proc Natl. Acad Sci USA 2000;97:7667-7669.

  7. Massagué J. The transforming growth factor-b famiiy. Annu Rev Cell Biol 1990;6:597-641.

  8. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-b (TGF-b). Growth Factors 1993;8:1-9.

  9. Massagué J, Blain SW, Lo RS. TGFb signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.

  10. Letterio JL, Roberts AB. Regulation of the immune response by TGF-b. Annu. Rev. lmmunol. 1998;16:137-161.

  11. Shuil MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-bl gene results in multifocal inflammatory response. Nature 1992;359:693-699.

  12. Kuíkarni AB, Karisson S. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol 1993;143:3-9.

  13. Sanford LP, Ormsby I, Gittenberger-de Groot A, et al. TGFb2 knockout mice have multiple developmental defects that are non overiapping with other TGFb knockout phenotypes. Development 1997;124:2659-2670.

  14. Kaartinen V, Voncken JW, Shuier C, et al. Abnormal lung development and cleft palate in mice lacking TGF-b3 indicates defects in epithelial-mesenchymal interaction. Nature Genet 1995;11:415-421.

  15. Border WA, Ruoslahti E. Transforming growth factor-b in disease: the dark side of tissue repair. J Clin lnvest 1992;90:1-7.

  16. Wahi SM. Transforming growth factor beta (TGF-b) in inflammation: a cause and a cure. J Clin lmmunol 1992;12:61-74.

  17. Munger JS, Harpel JG, Gleizes P-E, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-b: structural features and mechanisms of activation. Kidney Int 1997;51: 1376-1382.

  18. Murphy-Ulirich JE, Poczatek M. Activation of latent TGF-b by thrombospondin-l: mechanisms and physiology. Cytokine Growth Factor Rev 2000;11:59-69.

  19. Crawford SE, Stelimach V, Murphy-Ulirich JE, et al. Thrombospondin-1 is a major activator of TGF-b1 in vivo. Cell 1998; 93:1159-1170.

  20. Ribeiro SMF, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ulirich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent Transforming Growth Factor-b. J Biol Chem 1999; 274:13586-13593.

  21. Munger JS, Huang X, Kawakatsu H, et al. The integrin avb6 binds and activates latent TGFb1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96:319-328.

  22. Ciark DA, Coker R. Transforming growth factor-beta (TGF-beta). lnt J Biochem Cell Biol 1998;30:293-8.

  23. Massagué J. TGF-b signal transduction. Annu Rev Biochem 1998 67:753-791.

  24. Massagué J, Chen Y-G. Controlling TGF-b signalling. Genes Dev 2000;14:627.

  25. Massagué J. How cells read TGF-b signals. Nat Rev Mol Cell Biol 2000;1:169-178.

  26. Piek E, Heidin C-H, ten Dijke P. Specificity, diversity and regulation in TGF-b superfamily signaling. FASEB J 1999;13:2105-2124.

  27. Wrana JL. Regulation of Smad activity. Cell 2000;100:189-192.

  28. Hayashi H, Abdollah S, Qui Y, et al. The MAD-related protein Smad7 associates with the TGFP receptor and functions as an antagonist of TGFb signaling. Cell 1997; 89:1165-1173.

  29. Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7. a TGFb-inducible antagonist of TGF-b signaling. Nature 1997;389:631-635.

  30. Biobe GC, Schiemann WP, Lodish HF. Role of Transforming Growth Factor b in Human Disease. N Engl J Med 2000;342:1350-1358.

  31. López-Casillas F. El TGF-b (Transforming Growth Factor tipo beta), piedra angular en la nefropatía diabética. Rev Invest Clin 2000;52:487-490.

  32. Lang F, Kiingel K, Wagner CA, et al. Deranged transcriptional regulation of celivolume-sensitive kinase HSGK in diabetic nephropathy. Proc Natl Acad Sci USA 2000;97:8157-8162.

  33. Border WA, Okuda S, Languino LR, Spom MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor bl. Nature 1990;346:371-374.

  34. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-b by anti-TGF-b antibody attenuates kidney hypertrophy and enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45:522-530.

  35. Ziyadeh FN, Hoffi-nan BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular messangial matrix expansion by treatment with monoclonal antitransforming growth factor-b antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97:8015-8020.

  36. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor b is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818.

  37. Sharma K, Ziyadeh FN, Alzahabi B, et al. Increased renal production of transforming growth factor-bl in patients with type II diabetes. Diabetes 1997;46:854-859.

  38. Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-b protects against scarring in experimental kidney disease. Nature 1992;360:361-364.

  39. Isaka Y, Brees DK, lkegaya K, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996;2:418-23.

  40. Koib M, Margetts PJ, Galt T, et al. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am J Respir Crit Care Med 2001;163:770-7.

  41. Takeuchi Y, Kodama Y, Matsumoto T. Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity. J Biol Chem 1994;269:32634-8.

  42. Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 1999;274:4489-4492.

  43. Lin HY, Moustakas A, Knaus P, Weiis RG, Henis Yl, Lodish HF. The soluble exoplasmic domain of the type II transforming growth factor (TGF)-b receptor. J Biol Chem 1995;270:2747-2754.

  44. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activaron by soluble transforming growth factor beta type II receptor: a potencial new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999; 96:12719-12724.

  45. Isaka Y, Akagi Y, Ando Y, et al. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney lnt 1999;55:465-475.

  46. Böttinger EP, Factor VM, Tsang MLS, et al. The recombinant proregion of transforming growth factor bl (Latency-associated peptide) inhibits active transforming growth factor b1 in transgenic mice. Proc Natl Acad Sci USA 1996;93:5877-5882.

  47. Huang SS, Liu Q, Johnson FE, Konish Y, Huang JS. Transforming growth factor beta peptide antagonists and their conversion to partial agonists. J Biol Chem 1997;272:27155-27159.

  48. Hugo CPM, Pichler RP, Schuize-Lohoff E, et al. Thrombospondin peptides are potent inhibitors of messangial and glomerular endothelial cell proliferation in vitro and in vivo. Vjdney Int 1999;55:2236-2249.

  49. Akagi Y, lsaka Y, Aral M, et al. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney lnt 1996;50:148-55.

  50. Armendariz-Borunda J, LeGros L, Jr., Campollo O, Panduro A, Rincon AR. Antisense S-oligodeoxynucleotides down-regulate TGFbeta-production by Kupffer cells from CCI4-injured rat livers. Biochim Biophys Acta 1997;1353:241-252.

  51. Isaka Y, Tsujie M, Ando Y, et al. Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney fnt 2000;58:1885-92.

  52. Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN. Therapy with antisense TGF-betal oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol 2000;278:F628-34.

  53. Nakao A, Fujii M, Matsumara R, et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin lnvest 1999;104:5-11.

  54. Laping NJ, Grygielko E, Mathur A, et al. Inhibftion of TGF-beta 1-induced extracellular matrix wfth a novel selective inhibitor of the TGF-beta type I receptor kinase activity. J Am Soc Nephrol 2001;12:595A.

  55. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.

  56. López-Casillas F, Wrana JL, Massagué J. Betaglycan presents ligand to the TGF-b signaling receptor. Cell 1993;73:1435-1444.

  57. Headlines. Receptor of the third kind. Trends in Cell Biol 1993;3:334.

  58. López-Casillas F, Cheifetz S, Doody J, Andrés JL, Lane WS, Massagué J. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-b receptor system. Cell 1991;67:785-795.

  59. Ponce-Castañeda MV, Esparza-López J, Vilchis-Landeros MM, Mendoza R. V, López-Casillas F. Murine betaglycan primary structure, expression and glycosaminoglycan attachment sites. Biochim Biophys Acta 1998;1384:189-196.

  60. López-Casillas F, Payne HM, Andrés JL, Massagué J. Betaglycan can act as dual modulator of TGF-b access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 1994;124:557-568.

  61. Esparza-López J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, López-Casillas F. Ligand binding and functional properties of betaglycan, a coreceptor of transforming growth factor-b superfamily. Specialized binding regions for transforming growth factor-o and inhibin. A J Biol Chem 2001;276:14588-4596.

  62. Andres J, DeFalcis D, Noda M, Massagué J. Binding of two growth factor families to separate domains of the proteoglycan betaglycan. J Biol Chem 1992;267:5927-5930.

  63. Lewis KA, Gray PC, Blount AL, et al. Betaglycan binds inhibin and can mediate functional antagonism of activin signaling. Nature 2000;404:411-414.

  64. Bernard DJ, Chapman SC, Woodruff TK. Inhibin binding protein (inhBPlp/2O), betaglycan, and the continuing search for the inhibin receptor. Mol Endocrinol 2002;16:207-212.

  65. Andres JL, Stanley K, Cheifetz S, Massagué J. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-b. J Cell Biol 1989;109:3137-3145.

  66. Arribas J, López-Casillas F, Massagué J. Role of juxtamembrane domains of the transforming growth factor-a precursor and the b-amyloid protein in the regulated ectodomain shedding. J Biol Chem 1997;272:17160-17165.

  67. Vilchis-Landeros MM, Montiel JL, Mendoza V, Mendoza-Hemández G, López-Casillas F. Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-b neutralizing agent. Biochem J 2001;355:215-222.

  68. Attisano L, Wrana JL, López-Casillas F, Massagué J. TGF-b receptors and actions. Biochim Biophys Acta 1994;1222:71-80.

  69. López-Casillas F, Vilchis-Landeros MM, Mendoza M, Aguilar-Leon D, Hemández-Pando R. Anti-thymocyte serum-induced glomerulonephritis is prevented by recombinant soluble betaglycan, an inhibitor of Transforming Growth Factor-b. J Am Soc Nephrol 2001;12:684A.

  70. Bandyopadhyay A, Lopez Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, Sun L-Z. Antitumor activity of recombinant soluble betaglycan in human breast cancer xenograft. Cancer Research 2002;62:4690-4695.


  71. II. Participación del factor de transformación tumoral- en la regulación de la inflamación y la respuesta inmunológica


  73. Wahl SM. Transforming growth factor beta: the good, the bad and the ugly. J Exp Med 1994;180:1587-90.

  74. Letterio JJ, Roberts AB. Regulation of immune response by TGFb. Annu Rev Immunol 1998;16:137-61.

  75. Wahl SM, Mc Cartney-Francis N, Mergenhagen ES. Inflammatory and immunomodulatory release of TGF-b. Immunol Today 1989:10:258-262.

  76. Wahl Sm, Hunt DA, Wakefield LM, Mc Cartney-Francis N, Wahl LM, Roberts AB, Sporn MB. Transforming growth factor beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA1987;84:5788-5792.

  77. McCartney-Francis N, Mizel D, Wong L, Whal L, Whal S. TGF-b regulates production of growth factors and TGF-b by human peripheral blood monocytes. Growth Factors 1990;4:27-35.

  78. Wahl SM. Transforming growth factor beta in inflammation: a cause and a cure. J Clin Immunol 1992;12:61-68.

  79. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M, Roberts AB. Autoinduction of transforming growth factor beta is mediated by the AP-1 complex. Mol Cell Biol 1990;10:1492-1495.

  80. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor beta. Nature 1988;334:260-262.

  81. Sporn M, Roberts AB. Autocrine secretion-10 years later. Ann Int Med 1992;117:408-414.

  82. Kehrl JH, Wakefield LM, Robert AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn M, Fauci AS. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986;163: 037-50.

  83. Inge TH, Mc Coy KE, Susskind BM, Barret SK, Zhao G, Bear HD. Immunomodulatory effects of transforming growth factor beta on T lymphocytes. Induction of CD-8 expression in the CTLL-2 cell line in normal thymocytes. J Immunol 1992;148: 3847-53.

  84. Lomo J, Blomhof HK, Beiske K, Stokke T, Smeland EB. TGF-bl and cyclic AMP promotes apoptosis in resting human B lymphocytes. J Immunol 1995;154:1634-43.

  85. Czarniecki CW, Chiu HH, Wong GH, Mc Cabe SM, Palladino MA. Transforming growth factor beta I modulars the expression of class II histocompatibility antigens on human cells. J Immunol 1988;140:4217-4232.

  86. Tumer M, Chantry D, Katsikis T, Berger A, Brennan FM, Feldman M. Induction of interleukin 1 receptor antagonist protein by transforming growth factor beta. J Immunol 1991;21:1635-1639.

  87. Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 1987;166:991-999.

  88. Pinson DM, Le Claire RD, Lorsbach RB, Parmely MJ, Russell R. Regulation by transforming growth factor beta-1 of expression and function of the receptor for INF gamma on mouse macrophages. J Immunol 1992;149:2028-2038.

  89. Vodovotz Y, Bogdan C. Control of nitric oxide synthase expression by transforming growth factor beta: implications for homeostasis. Prog Growth Factor Res 1994;5:341-351.

  90. Schmitt E, Hoehn P, Hueis C, Goedert S, Palm N, Rude E, Germann T. T helper type 1 development of naive CD-4 T cells requires the coordinated action of interleukin 12 and interferon gamma and is inhibited by transforming growth factor beta. Eur J Immunol 1994;24:793-798.

  91. Strober W, Kelsali B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, Neurath M. Reciprocal IFN gamma and TGF-b responses regulate the occurrence of mucosal inflammation. Immunol Today 1997;18:61-64.

  92. Maeda Y, Kuwahara H, Ichimura Y, Ohtsuki M, Kurakata S, Shirahishi A. TGFb enhances macrophage ability to produce IL-10 in normal and tumor bearing mice. J Immunol 1995;15:4926-4932.

  93. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Haffer DA. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor beta-1 secreting Th-3 cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996;98: 70-77.

  94. Tossi Z, Ellner J. The role of TGFb in the pathogenesis of human tuberculosis. Clin Immunol Immunopathol 1998;87:107-114.

  95. Shull MM, Ormsby I, Kier AB, Pawloski S, Diebold R, Yin M, Alien R, Sidman C, Proetzel G, Calvin D. Targeted disruption of the mouse transforming growth factor beta 1 gene results in multifocal inflammatory disease. Nature 1992;359:693-99.

  96. Barral Netto M, Barral A, Brownell CE, Skeiki YA, Ellingsworth LR, Twardzic DR, Reed SG. Transforming growth factor beta in leishmanial infection; a parasite escape mechanism. Science 1992;257:545-48.

  97. Gazzinelli RT, Oswald IP, Hieny S, James SL, Sher A. The microbicidal activity of interferon gamma treated macrophages against Trypanosoma cruzi, involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhabitable by interleukin 10 and transforming growth factor beta. Eur J Immunol 1992;22:2501-06.

  98. Barral Neto M, Barral A, Brodskyn C, Carvalho EM. Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunol 1995,17:21-28.

  99. King CL, Mahanty S, Kumarasawami V, Abrams JS, Regunthan J, Jeyamaran K, Ottesen EA, Nutman TB. Cytokine control of parasite specific anergy in human lymphatic filariasis. J Clin Invest 1993,92:1667-1673.

  100. Lotz M, Seth P. TGF beta and HIV. Annu NY Acad Sci 1993,685:501-511.

  101. Maltman J, Pargnell IB, Graham GJ. Specificity and reciprocity in the interactions between TGF- and macrophage inflammatory protein 1 -alpha. J Immunol 1996;156: 1566-1571.

  102. Rook GAW, Hemández Pando R. The pathogenesis of tuberculosis. Annu Rev Microbiol 1996;:50:259-284.

  103. Hernández Pando R, Orozco EH, Arriaga K, Sampieri A, Larriva Sahd J, Madrid MV. Analysis of the local kinetics and localization of interleukin 1 alpha, tumor necrosis factor alpha and transforming growth factor beta during the course of experimental pulmonary tuberculosis. Immunology 1997;90:607-17.

  104. Hirsch C, Ellner J, Blinkhom R, Tossi Z. In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta. Proc Natl Acad Scien 1997;94:3926-3931.

  105. Shevaen EM. CD4 + CD25 + suppressor T cells more questions than answers. Nat Rev Immunol 2002;2:389-400.


  106. III. TGF-β: receptores, señales y acciones


  108. 1 . Massagué J. The transforming growth factor-p family. Annu Rev Cell Biol 1990;6:597-641.

  109. Kingsley DM. The TGF-b superfamily: new members, new receptors, and new genetics tests of function in different organisms. Genes Dev 1994;8:133-146.

  110. Massagué J, Blain SW, Lo RS. TGFb signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.

  111. Biobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor P in human disease. N Engl J Med 2000; 342:1350-1358.

  112. Massagué J. TGF-b signal transduction. Annu Rev Biochem 1998;67:753-791.

  113. Massagué J, Chen Y-G. Controlling TGF-b signaling. Genes Dev 2000;14:627-644.

  114. Massagué J. How cells read TGF-b signals. Nat Rev Mol Cell Biol 2000;1:169-178.

  115. Wrana JL. Regulation of Smad activity. Cell 2000; 100:189-192.

  116. Massagué J, Attisano L, Wrana JL. The TGF-b family and its composite receptors. Trends Cell Biol 1994;4:172-178.

  117. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-b receptor. Nature 1994;370:341-347.

  118. Huse M, Muir TW, Xu L, Chen Y-G, Kuriyan J, Massagué J. The TGFb receptor activation process: an inhibitor- to substrate binding switch. Mol Cells 2001;8:671-682.

  119. Macías-Silva M, Abdollah S, Hoodiess PA, Pirone R, Attisano L, Wrana JL. MADR2 is a substrate of the TGFb receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996; 87:1215-1224.

  120. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 1998; 95:779-91.

  121. Xu L, Chen YG, Massague J. The nuclear import function of Smad2 is masked by SARA and unmasked by TGFbeta-dependent phosphorylation. Nat Cell Biol 2000-2:559-62.

  122. Nako A, Afrakhte M, Moren A, et al. Identification of Smad7. a TGFb-inducible antagonist of TGF-b signaling. Nature 1997;389:631-635.

  123. Laiho M, Weis FMB, Massagué J. Concomitant loss of transforming growth factor-b receptor types I and II in cell mutants resistant to TGF-b. J. Biol Chem 1990; 265:18518-18524.

  124. Laiho M, Weis FMB, Boyd FT, Ignotz RA, Massagué J. Responsiveness to transforming growth factor-p restored by complementation between cells detective in TGF-b receptors I and ll. J Biol Chem 1991;266:9108-9112.

  125. Seoane J, Pouponnot C, Stalier P, Schader M, Eilers M, Massague J. TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor pl5iNK4b. Nat Cell Biol 2001;3:400-8.

  126. Hata A, Seoane J, Lagna G, Montalvo E, Hemmati-Brivanlou A, Massague J. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP- Smad and Olf signaling pathways. Cell 2000;100:229-40.

  127. Gripp KW, Wotton D, Edwards MC, et al. Mutations in TGIF cause holoprosencephaly and link NODAL signaling to human neural axis determination. Nat Genet 2000;25:205-8.

  128. Lo RS, Wotton D, Massague J. Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. Embo J 2001;20:128-36.

  129. Hahn SA, Schutte M, Hoque ATMS, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q2l. l. Science 1996;271:350-353.

  130. Nurse P. A long twentieth century of the cell cycle and beyond. Cell 2000;100:71-78.

  131. Murray A, Hunt T. The Cell Cycle, an introduction. New York: Oxford University Press, lnc., 1993.

  132. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators od Glphase progression. Genes Dev 1999;13:1501-1512.

  133. Warner BJ, Blain SW, Seoane J, Massague J. Myc down regulation by transforming growth factor beta required for activation of the pl5(Ink4b) G(l) arrest pathway. Mol Cell Biol 1999;19:5913-22.

  134. Chen C-R, Kang Y, Siegel PM, Massague J. E2F4/5 and p107 as Smad cofactors linking the TGFb receptor to c-myc repression. Cell 2002;110:19-32.




2020     |     www.medigraphic.com